Collect information about WILLFACT or WILFACTIN in their real life clinical use and identify the therapeutic practices in an international environment.
Non-interventional, prospective, non comparative, international, multicentre study.
Study Type
OBSERVATIONAL
Enrollment
80
Hopital des enfants Reine Fabiola
Antwerp, Belgium
UZA hopital universitaire
Edegem, Belgium
University Hospital
Documentation of product consumption data
Product consumption (VWF International Units) by analysis of posology, frequency in relation to the severity of bleeding, type of surgery and other clinical situations.
Time frame: at each follow-up visit, up to 24 months
Collection and analysis of adverse events and VWF immunological safety
Adverse event (type, seriousness, severity, frequency, outcome), anti VWF-antibody and anti FVIII-antibody.
Time frame: at each follow-up visit, up to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Brno, Czechia
University Central Hospital
Helsinki, Finland
Charité Universitätsmedizin
Berlin, Germany
GZRR Gerinnungszentrum Rhein/ Ruhr
Duisburg, Germany
Universitatsklinikum
Essen, Germany
Goethe Universitat
Frankfurt, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Werlhof-Institut für Hämostaseologie GmbH
Hanover, Germany
...and 8 more locations